As aberrant EGFR signaling is critically involved in the development and progression of NSCLC, tyrosine kinase inhibitors (TKIs) have been developed to successfully treat NSCLC patients in the past decades. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.